Loading company…
Mingsight develops ophthalmic drugs, including a PKC inhibitor for diabetic retinopathy.
Founded in 2011 in Shenzhen, China, Mingsight researches and develops ophthalmic medicines. Its candidate MS-533 is a selective protein kinase C inhibitor intended for diabetic retinopathy and autoimmune diseases. The company planned to use pre-Series B funding for clinical research and production of MS-533 for CLL and DME treatment. Co-founders include CEO Kai Zhang and Dr. Michael R. Niesman.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in